Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twenty-nine research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $217.2593.
Several brokerages have weighed in on BIIB. The Goldman Sachs Group upped their target price on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Truist Financial lowered their target price on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a report on Monday, April 13th. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and upped their target price for the stock from $185.00 to $225.00 in a report on Wednesday, April 22nd. Rothschild & Co Redburn upped their price objective on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Finally, Wedbush upped their price objective on Biogen from $191.00 to $196.00 and gave the stock a “neutral” rating in a research note on Thursday, April 30th.
View Our Latest Stock Analysis on BIIB
Biogen Price Performance
Biogen (NASDAQ:BIIB – Get Free Report) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the business earned $3.02 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts predict that Biogen will post 14.18 EPS for the current fiscal year.
Institutional Investors Weigh In On Biogen
Hedge funds have recently made changes to their positions in the stock. Reflection Asset Management purchased a new stake in shares of Biogen during the 4th quarter worth $25,000. WPG Advisers LLC lifted its stake in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the last quarter. Accredited Wealth Management LLC lifted its stake in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Biogen during the 4th quarter worth $30,000. Finally, WFA of San Diego LLC purchased a new stake in shares of Biogen during the 2nd quarter worth $32,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
About Biogen
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Further Reading
- Five stocks we like better than Biogen
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
